Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285386790> ?p ?o ?g. }
- W4285386790 endingPage "1806" @default.
- W4285386790 startingPage "1797" @default.
- W4285386790 abstract "Objective This phase 3 confirmatory diabetes mellitus treatment study compared the safety and efficacy of Rapilin and NovoRapid insulin asparts in combination with metformin.Methods This 24-week, open-label, randomized, active-controlled, noninferiority phase 3 confirmatory study conducted across centers in China aimed to enroll patients with type 2 diabetes mellitus and blood sugar glucose inadequately controlled by oral antidiabetic drugs. Randomized patients received subcutaneous mealtime Rapilin or NovoRapid (3:1) injections, with metformin. The primary objectives were to demonstrate noninferiority (margin of 0.4%) in HbA1c change from baseline and compare safety profiles of Rapilin versus NovoRapid after 24 weeks. Secondary outcomes included 2-h postprandial plasma glucose (PPG), fasting plasma glucose (FPG), and patients achieving HbA1c <7.0% and ≤6.5%.Results 590 patients with type 2 diabetes mellitus were randomized to Rapilin (n = 441) and NovoRapid (n = 149) groups. After 24 weeks, the mean HbA1c change from baseline was −2.20% (Rapilin) and −2.32% (NovoRapid); the estimated treatment difference based on least-square means was 0.04% (95% CI: −0.17, 0.26), meeting the noninferiority criteria for Rapilin versus NovoRapid. Comparable improvements were reported for mean 2-hour PPG (6.14 and 6.29 mmol/L), FPG (2.02 and 1.70 mmol/L), and patients with HbA1c <7.0% (52.6% and 51.0%) and ≤6.5% (34.2% and 30.9%), in the Rapilin and NovoRapid groups, respectively, with no significant safety or immunogenicity outcome differences.Conclusions Rapilin demonstrated non-inferior glycemic control, and matching safety and immunogenicity to NovoRapid in patients with type 2 diabetes mellitus also receiving metformin over 24 weeks.Trial registration ChiCTR20003129041" @default.
- W4285386790 created "2022-07-14" @default.
- W4285386790 creator A5000159943 @default.
- W4285386790 creator A5000597313 @default.
- W4285386790 creator A5008073398 @default.
- W4285386790 creator A5012799196 @default.
- W4285386790 creator A5014066735 @default.
- W4285386790 creator A5016666115 @default.
- W4285386790 creator A5021052031 @default.
- W4285386790 creator A5021589498 @default.
- W4285386790 creator A5021983750 @default.
- W4285386790 creator A5023624619 @default.
- W4285386790 creator A5027310979 @default.
- W4285386790 creator A5028493104 @default.
- W4285386790 creator A5030161456 @default.
- W4285386790 creator A5034608423 @default.
- W4285386790 creator A5051970233 @default.
- W4285386790 creator A5052508867 @default.
- W4285386790 creator A5053447705 @default.
- W4285386790 creator A5065719285 @default.
- W4285386790 creator A5074446865 @default.
- W4285386790 creator A5079860164 @default.
- W4285386790 creator A5083581289 @default.
- W4285386790 creator A5090119023 @default.
- W4285386790 date "2022-07-22" @default.
- W4285386790 modified "2023-10-14" @default.
- W4285386790 title "Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial" @default.
- W4285386790 cites W1605338960 @default.
- W4285386790 cites W1896782898 @default.
- W4285386790 cites W2000848855 @default.
- W4285386790 cites W2001295992 @default.
- W4285386790 cites W2004598737 @default.
- W4285386790 cites W2005300371 @default.
- W4285386790 cites W2024157409 @default.
- W4285386790 cites W2027974633 @default.
- W4285386790 cites W2079629654 @default.
- W4285386790 cites W2091225717 @default.
- W4285386790 cites W2126196596 @default.
- W4285386790 cites W2156383186 @default.
- W4285386790 cites W2161872536 @default.
- W4285386790 cites W2174441009 @default.
- W4285386790 cites W2190748907 @default.
- W4285386790 cites W2587012072 @default.
- W4285386790 cites W2599265996 @default.
- W4285386790 cites W2604725688 @default.
- W4285386790 cites W2793289663 @default.
- W4285386790 cites W2912910847 @default.
- W4285386790 cites W2944768911 @default.
- W4285386790 cites W2950796007 @default.
- W4285386790 cites W2972869264 @default.
- W4285386790 cites W2983065703 @default.
- W4285386790 cites W2992423941 @default.
- W4285386790 cites W3174601009 @default.
- W4285386790 cites W39672263 @default.
- W4285386790 cites W4246340431 @default.
- W4285386790 cites W4247704066 @default.
- W4285386790 cites W4250822724 @default.
- W4285386790 doi "https://doi.org/10.1080/03007995.2022.2100652" @default.
- W4285386790 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35833285" @default.
- W4285386790 hasPublicationYear "2022" @default.
- W4285386790 type Work @default.
- W4285386790 citedByCount "0" @default.
- W4285386790 crossrefType "journal-article" @default.
- W4285386790 hasAuthorship W4285386790A5000159943 @default.
- W4285386790 hasAuthorship W4285386790A5000597313 @default.
- W4285386790 hasAuthorship W4285386790A5008073398 @default.
- W4285386790 hasAuthorship W4285386790A5012799196 @default.
- W4285386790 hasAuthorship W4285386790A5014066735 @default.
- W4285386790 hasAuthorship W4285386790A5016666115 @default.
- W4285386790 hasAuthorship W4285386790A5021052031 @default.
- W4285386790 hasAuthorship W4285386790A5021589498 @default.
- W4285386790 hasAuthorship W4285386790A5021983750 @default.
- W4285386790 hasAuthorship W4285386790A5023624619 @default.
- W4285386790 hasAuthorship W4285386790A5027310979 @default.
- W4285386790 hasAuthorship W4285386790A5028493104 @default.
- W4285386790 hasAuthorship W4285386790A5030161456 @default.
- W4285386790 hasAuthorship W4285386790A5034608423 @default.
- W4285386790 hasAuthorship W4285386790A5051970233 @default.
- W4285386790 hasAuthorship W4285386790A5052508867 @default.
- W4285386790 hasAuthorship W4285386790A5053447705 @default.
- W4285386790 hasAuthorship W4285386790A5065719285 @default.
- W4285386790 hasAuthorship W4285386790A5074446865 @default.
- W4285386790 hasAuthorship W4285386790A5079860164 @default.
- W4285386790 hasAuthorship W4285386790A5083581289 @default.
- W4285386790 hasAuthorship W4285386790A5090119023 @default.
- W4285386790 hasConcept C126322002 @default.
- W4285386790 hasConcept C134018914 @default.
- W4285386790 hasConcept C168563851 @default.
- W4285386790 hasConcept C197934379 @default.
- W4285386790 hasConcept C2777180221 @default.
- W4285386790 hasConcept C2778199505 @default.
- W4285386790 hasConcept C2779306644 @default.
- W4285386790 hasConcept C2780323712 @default.
- W4285386790 hasConcept C2780473172 @default.
- W4285386790 hasConcept C2910068830 @default.
- W4285386790 hasConcept C555293320 @default.
- W4285386790 hasConcept C71924100 @default.
- W4285386790 hasConcept C90924648 @default.